DOI QR코드

DOI QR Code

Saliva Supernatant miR-21: a Novel Potential Biomarker for Esophageal Cancer Detection

  • Xie, Zi-Jun (Department of Gastroenterology, Guangdong Academy of Medical Sciences, Guangdong General Hospital) ;
  • Chen, Gang (Department of Thoracic Surgery, Guangdong Academy of Medical Sciences, Guangdong General Hospital) ;
  • Zhang, Xu-Chao (Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, Guangdong General Hospital) ;
  • Li, Dong-Feng (Research Center of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong General Hospital) ;
  • Huang, Jian (Physical Examination Center of East Ward, Guangdong Academy of Medical Sciences, Guangdong General Hospital) ;
  • Li, Zi-Jun (Department of Gastroenterology, Guangdong Academy of Medical Sciences, Guangdong General Hospital)
  • Published : 2012.12.31

Abstract

Objective: To identify whether saliva supernatant miR-21 can serve as a novel potential biomarker in patients with esophageal cancer (EC). Methods: 32 patients with EC and 16 healthy controls were recruited in this study. Total RNA was extracted from saliva supernatant samples for measurement of miR-21 levels using RT-qPCR and relationships between miR-21 levels and clinical characteristics of EC patients were analyzed. Results: miR-21 was significantly higher in the EC than control groups. The sensitivity and specificity were 84.4% and 62.5% respectively. Supernatant miR-21 levels showed no significant correlation with cancer stage, differentiation and nodal metastasis. Conclusions: Saliva supernatant miR-21 may be a novel biomarker for EC.

Keywords

References

  1. Akobeng AK (2007). Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr, 96, 644-7. https://doi.org/10.1111/j.1651-2227.2006.00178.x
  2. Alvarez-Garcia I, Miska EA (2005). MicroRNA functions in animal development and human disease. Development, 132, 4653-62. https://doi.org/10.1242/dev.02073
  3. Bonci D (2010). MicroRNA-21 as therapeutic target in cancer and cardiovascular disease. Recent Pat Cardiovasc Drug Discov, 5, 156-61. https://doi.org/10.2174/157489010793351962
  4. Chen X, Ba Y, Ma L, et al (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006. https://doi.org/10.1038/cr.2008.282
  5. Feber A, Xi L, Luketich JD, et al (2008). MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg, 135, 255-60. https://doi.org/10.1016/j.jtcvs.2007.08.055
  6. Gilad S, Meiri E, Yogev Y, et al (2008). Serum microRNAs are promising novel biomarkers. PLoS One, 3, e3148. https://doi.org/10.1371/journal.pone.0003148
  7. Iguchi H, Kosaka N, Ochiya T (2010). Secretory microRNAs as a versatile communication tool. Commun Integr Biol, 3, 478-81. https://doi.org/10.4161/cib.3.5.12693
  8. Jazbutyte V, Thum T (2010). MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets, 11, 926-35. https://doi.org/10.2174/138945010791591403
  9. Kim T, Grobmyer SR, Smith R, et al (2011). Hochwald SN. Esophageal cancer--the five year survivors. J Surg Oncol, 103, 179-83. https://doi.org/10.1002/jso.21784
  10. Komatsu S, Ichikawa D, Takeshita H, et al (2011). Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer, 105, 104-11. https://doi.org/10.1038/bjc.2011.198
  11. Kosaka N, Iguchi H, Yoshioka Y, et al (2010). Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem, 285, 17442-52. https://doi.org/10.1074/jbc.M110.107821
  12. Lambert R, Hainaut P (2007). Esophageal cancer: cases and causes (part I). Endoscopy, 39, 550-5. https://doi.org/10.1055/s-2007-966530
  13. Lee YH, Wong DT (2009). Saliva: an emerging biofluid for early detection of diseases. Am J Dent, 22, 241-8.
  14. Li XY, Guo YB, Su M, et al (2011). Association of mitochondrial haplogroup D and risk of esophageal cancer in Taihang Mountain and Chaoshan areas in China. Mitochondrion, 11, 27-32. https://doi.org/10.1016/j.mito.2010.06.005
  15. Li Y, Elashoff D, Oh M, et al (2006). Wong DT. Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol, 24, 1754-60. https://doi.org/10.1200/JCO.2005.03.7598
  16. Li Y, Jiang Z, Xu L, et al (2011). Stability analysis of liver cancer-related microRNAs. Acta Biochim Biophys Sin (Shanghai), 43, 69-78. https://doi.org/10.1093/abbs/gmq114
  17. Lin J, Zeng R, Cao W, et al (2011). Hot beverage and food intake and esophageal cancer in southern China. Asian Pac J Cancer Prev, 12, 2189-92.
  18. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8. https://doi.org/10.1006/meth.2001.1262
  19. Mbulaiteye SM, Walters M, Engels EA, et al (2006). High levels of Epstein-Barr virus DNA in saliva and peripheral blood from Ugandan mother-child pairs. J Infect Dis, 193, 422-6. https://doi.org/10.1086/499277
  20. McDonald JS, Milosevic D, Reddi HV, et al (2011). Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem, 57, 833-40. https://doi.org/10.1373/clinchem.2010.157198
  21. Michael A, Bajracharya SD, Yuen PS, et al (2010). Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis, 16, 34-8. https://doi.org/10.1111/j.1601-0825.2009.01604.x
  22. Mishima T, Akagi I, Miyashita M, et al (2009). Study of MicroRNA expression profiles of esophageal cancer. J Nippon Med Sch, 76, 43. https://doi.org/10.1272/jnms.76.43
  23. Park NJ, Zhou H, Elashoff D, et al (2009). Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res, 15, 5473-77. https://doi.org/10.1158/1078-0432.CCR-09-0736
  24. Patel RS, Jakymiw A, Yao B, et al (2011). High resolution of microRNA signatures in human whole saliva. Arch Oral Biol, 56, 1506-13. https://doi.org/10.1016/j.archoralbio.2011.05.015
  25. Rabinowits G, Gercel-Taylor C, Day JM, et al (2009). Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer, 10, 42-6. https://doi.org/10.3816/CLC.2009.n.006
  26. Rastogi A, Puli S, El-Serag HB, et al (2008). Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc, 67, 394-8. https://doi.org/10.1016/j.gie.2007.07.019
  27. Schipper RG, Silletti E, Vingerhoeds MH (2007). Saliva as research material: biochemical, physicochemical and practical aspects. Arch Oral Biol, 52, 1114-35. https://doi.org/10.1016/j.archoralbio.2007.06.009
  28. Smith CM, Watson DI, Michael MZ, Hussey DJ (2010). MicroRNAs, development of Barrett's esophagus, and progression to esophageal adenocarcinoma. World J Gastroenterol, 16, 531-7. https://doi.org/10.3748/wjg.v16.i5.531
  29. Streckfus C, Bigler L, Dellinger T, et al (2001).Reliability assessment of soluble c-erbB-2 concentrations in the saliva of healthy women and men. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 91, 174-9. https://doi.org/10.1067/moe.2001.111758
  30. Streckfus C, Bigler L, Dellinger T, et al (2000). The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res, 6, 2363-70.
  31. Streckfus C, Bigler L, Dellinger T, et al (1999). CA 15-3 and c-erbB-2 presence in the saliva of women. Clin Oral Investig, 3, 138-43. https://doi.org/10.1007/s007840050092
  32. Su M, Liu M, Tian DP, et al (2007). Temporal trends of esophageal cancer during 1995-2004 in Nanao Island, an extremely high-risk area in China. Eur J Epidemio, 22, 43-8. https://doi.org/10.1007/s10654-006-9086-x
  33. Taylor DD, Gercel-Taylor C (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol, 110, 13-21. https://doi.org/10.1016/j.ygyno.2008.04.033
  34. van Soest EM, Dieleman JP, Siersema PD, et al (2005). Increasing incidence of Barrett's oesophagus in the general population. Gut, 54, 1062-6. https://doi.org/10.1136/gut.2004.063685
  35. Weber JA, Baxter DH, Zhang S, et al (2010). The microRNA spectrum in 12 body fluids. Clin Chem, 56, 1733-41. https://doi.org/10.1373/clinchem.2010.147405
  36. Wiklund ED, Gao S, Hulf T, et al (2011). MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS One, 6, e27840. https://doi.org/10.1371/journal.pone.0027840
  37. Wong DT (2006). Towards a simple, saliva-based test for the detection of oral cancer 'oral fluid (saliva), which is the mirror of the body, is a perfect medium to be explored for health and disease surveillance'. Expert Rev Mol Diagn, 6, 267-72. https://doi.org/10.1586/14737159.6.3.267
  38. Xu XC (2009). Risk factors and gene expression in esophageal cancer. Methods Mol Biol, 471, 335-60. https://doi.org/10.1007/978-1-59745-416-2_17
  39. Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M (2012). Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res, 93, 555-62. https://doi.org/10.1093/cvr/cvr266
  40. Zhou SL, Wang LD (2010). Circulating microRNAs: novel biomarkers for esophageal cancer. World J Gastroenterol, 16, 2348-54. https://doi.org/10.3748/wjg.v16.i19.2348

Cited by

  1. The clinical utility of microRNA-21 as novel biomarker for diagnosing human cancers vol.36, pp.3, 2015, https://doi.org/10.1007/s13277-014-2806-z
  2. The Potential Use of Salivary miRNAs as Promising Biomarkers for Detection of Cancer: A Meta-Analysis vol.11, pp.11, 2016, https://doi.org/10.1371/journal.pone.0166303
  3. Significance of microRNA expression in body fluids in the diagnosis of gastrointestinal tumors vol.155, pp.1, 2014, https://doi.org/10.1556/OH.2014.29789
  4. Cancer Salivary Biomarkers for Tumours Distant to the Oral Cavity vol.17, pp.9, 2016, https://doi.org/10.3390/ijms17091531